Tag - Jonathan Chang

Markets

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

Leerink slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $4 from $15, but maintained its “outperform” rating after the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary...

July 27, 2023

Markets

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

SVB Leerink upgraded Calithera Biosciences (NASDAQ:CALA) to “outperform” from “market perform” and raised its price target to $3 from $1. The stock closed at 49 cents on Jan. 19. “We conducted a deeper dive on...

January 20, 2022

Markets

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink raised its price target for TCR2 Therapeutics (NASDAQ:TCRR) to $41 from $28, citing positive interim data from the ongoing Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing...

December 15, 2020

Markets

SVB Leerink starts Athenex at OP; PT $22

SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...

October 26, 2020

Markets

SVB Leerink cuts Rubius Therapeutics to MP; TP to $4 from $19

SVB Leerink downgraded Rubius Therapeutics (NASDAQ:RUBY) to “market perform” from “outperform” and slashed its price target to $4 from $19 after the company discontinued development of RTX-134 for the treatment of...

March 13, 2020

Markets

SVB Leerink starts Harpoon Therapeutics at OP; PT $25

SVB Leerink initiated coverage of Harpoon Therapeutics (NASDAQ:HARP) with an “outperform” rating and $25 price target. The stock closed at $17.01 on March 4. Harpoon is a clinical-stage immuno-oncology company...

March 5, 2019

Tag - Jonathan Chang

Leerink slashes Mersana PT to $4 after UPLIFT trial fails

SVB Leerink ups Calithera to OP from MP; PT to $3 from $1

SVB Leerink ups TCR2 Therapeutics PT to $41 from $28

SVB Leerink starts Athenex at OP; PT $22

SVB Leerink cuts Rubius Therapeutics to MP; TP to $4 from $19

SVB Leerink starts Harpoon Therapeutics at OP; PT $25

General

More